A Knight Therapeutics Inc. official still believes a rare pediatric disease priority review voucher is worth more than a tropical disease PRV, even though sale prices for both do not reflect it.
Knight received nearly double the price for its tropical disease PRV as BioMarin Pharmaceutical Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?